Phytochemical characterization, antioxidant and antibacterial activities of crude extracts of Anisomeles malabarica and Coldenia procumbens.

The aim of this study was to determine the phytochemical profile, antibacterial and antioxidant activities of crude aqueous leaf extracts of Anisomeles malabarica and Coldenia procumbens. The predominant components present in these crude extracts of test plants identified using gas chromatography-mass spectrometry (GC-MS) analysis in both plant extracts were phytochemicals including flavonoids, tannins, terpenoids, and phenols. The antibacterial activity of crude extracts of these plants against bacterial pathogens including Escherichia coli, Bacillus subtilis, Shigella sp., Salmonella paratyphi A and B, Proteus mirabilis, Proteus vulgaris, Pseudomonas sp. Klebsiella pneumoniae, and Staphylococcus aureus were examined. Data demonstrated that the extracts of A. malabarica and C. procumbens exhibited significant antibacterial activity against B.subtilis and P.vulgaris at the concentration of 50 mg/ml. A. malabarica aqueous extract displayed significant antioxidant activity on 2,2-diphenyl-1-picrylhydrazl (DPPH), fluorescence recovery after photobleaching (FRAP) and hydrogen peroxide (H2O2) free radicals at the concentration of 90 mg/ml. The antioxidant activity was significantly higher with A. malabarica than extract of C. procumbens. Evidence indicates that both plant extracts may possess significant pharmaceutical potential as antibacterial and antioxidant agents.

Effect of Prunetin on Streptozotocin-Induced Diabetic Nephropathy in Rats - a Biochemical and Molecular Approach

In the modern era, chronic kidney failure due to diabetes has spread across the globe. Prunetin (PRU), a component of herbal medicines, has a broad variety of pharmacological activities; these may help to slow the onset of diabetic kidney disease. The anti-nephropathic effects of PRU have not yet been reported. The present study explored the potential nephroprotective actions of PRU in diabetic rats. For 28 days, nephropathic rats were given oral doses of PRU (20, 40, and 80 mg/kg). Body weight, blood urea, creatinine, total protein, lipid profile, liver marker enzymes, carbohydrate metabolic enzymes, C-reactive protein, antioxidants, lipid peroxidative indicators, and the expression of insulin receptor substrate 1 (IRS-1) and glucose transporter 2 (GLUT-2) mRNA genes were all examined. Histological examinations of the kidneys, liver, and pancreas were also performed.The oral treatment of PRU drastically lowered the blood glucose, HbA1c, blood urea, creatinine, serum glutamic-oxaloacetic transaminase, serum glutamic pyruvic transaminase, alkaline phosphatase, lipid profile, and hexokinase. Meanwhile, the levels of fructose 1,6-bisphosphatase, glucose-6-phosphatase, and phosphoenol pyruvate carboxykinase were all elevated, but glucose-6-phosphate dehydrogenase dropped significantly. Inflammatory marker antioxidants and lipid peroxidative markers were also less persistent due to this administration. PRU upregulated the IRS-1 and GLUT-2 gene expression in the nephropathic group.The possible renoprotective properties of PRU were validated by histopathology of the liver, kidney, and pancreatic tissues. It is therefore proposed that PRU (80 mg/kg) has considerable renoprotective benefits in diabetic nephropathy in rats.

Attenuation of lipid metabolic abnormalities, proinflammatory cytokines, and matrix metalloproteinase expression by biochanin-A in isoproterenol-induced myocardial infarction in rats.

In the present study, we assessed the therapeutic potential of Biochanin-A (BCA) (10 mg/kg BW/day) pretreatment for 30 days on lipid metabolic abnormalities, proinflammatory cytokines and matrix metalloproteinase expression in isoproterenol (ISO)-induced myocardial infarction (MI) in rats. We measured the potential role of BCA on tissue and circulatory lipid profiles as well as on lipid metabolic enzymes: serum inflammatory cytokines (TNF-α, IL-1α, IL-1ß, IL-6 and MCP1) and serum Matrix Metalloproteinases (particularly, MMP-2 and MMP-9) together with mRNA expressions of TNF-α, IL-6, MMP-2 and MMP-9 by RT-PCR analysis. Administration of ISO to rats significantly distorted their lipid metabolism and augmented inflammatory process, MMP expression and proteolytic activity. In addition, pretreatment with BCA of ISO-induced MI rats significantly reestablished the altered lipid metabolism and concealed the inflammation of cytokines. BCA suppressed the expressions of proinflammatory cytokines and MMPs in ISO-induced MI in rats when compared to normal untreated MI rats. Hence, these results established that BCA could improve the pathological processes of myocardial remodeling which was confirmed by histopathology of heart in MI rats and might be an effective beneficial ingredient for the management of heart failure disorders.